Regeneron (REGN)
Quick facts
| Ticker | REGN (NASDAQ) |
|---|
Marketed products
- Dupixent · Immunology · revenue 14600
Dupixent blocks the interleukin-4 receptor, a key player in the immune system's inflammatory response. - Vegf Trap · Oncology · revenue 9800
- Libtayo · Oncology · revenue 1452
Cemiplimab-rwlc binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors. - Inmazeb · Immunology · revenue 76
Inmazeb works by binding to the Ebola virus, preventing it from interacting with host cells and thereby reducing the severity of the disease. - Inmazeb · Infectious Disease · revenue 76
Inmazeb works by binding to and neutralizing the Ebola virus. - Inmazeb · Immunology · revenue 76
Inmazeb works by binding to the Ebola virus, preventing it from interacting with host cells. - Ronapreve · Infectious Disease
- Evkeeza · Metabolic
Evkeeza works by blocking the action of Angiopoietin-related protein 3, a protein that helps regulate cholesterol levels in the blood. - EVKEEZA · Metabolic
- Veopoz · Immunology
Veopoz works by blocking the activity of Complement C5, a protein that contributes to inflammation. - VEOPOZ · Other
Pozelimab-bbfg blocks C5 cleavage, preventing C5a and C5b formation and inhibiting terminal complement activation. - Arcalyst · Rare Disease
Arcalyst works by binding to Interleukin-1 beta, preventing its interaction with its receptor and reducing inflammation.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: